About 2,800 results
Daiichi Sankyo, Merck
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
U.S. News Room - Daiichi Sankyo US
WEB5 days ago · About Daiichi Sankyo ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of …
Daiichi Sankyo-Merck's 'guided-missile' cancer drug …
WEB5 days ago · Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
WEB4 days ago · Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, …
Daiichi Sankyo and MSD’s ADC improves progression-free survival …
WEB4 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd …
Daiichi wants to go it alone in search for targeted …
WEB5 days ago · Sep 17, 2024. The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this time it might not need a partner to get it over the line ...
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, …
WEB5 days ago · iStock, mesh cube. Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell …
- People also ask
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift ...
WEB2 days ago · As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first …
AZ and Daiichi's TROP2 ADC shows promise in first-line …
WEB4 days ago · Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced...
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
WEB5 days ago · A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...
Daiichi Sankyo - Patritumab Deruxtecan Demonstrated Statistically ...
WEB4 days ago · Daiichi Sankyo and Merck entered into a global collaboration in October 2023 to jointly develop and commercialize patritumab deruxtecan (HER3-DXd), ifinatamab …
- Some results have been removed
